Back

Fine Molecular Tuning of Chimeric Antigen Receptors through Hinge Length Optimization

McComb, S.; Nguyen, T.; Henry, K. A.; Bloemberg, D.; Maclean, S.; Gilbert, R.; Gadoury, C.; Pon, R.; Sulea, T.; Zhu, Q.; Weeratna, R. D.

2020-10-30 immunology
10.1101/2020.10.30.360925 bioRxiv
Show abstract

BackgroundChimeric antigen receptor (CAR) technology has revolutionized the treatment of B-cell malignancies and steady progress is being made towards CAR-immunotherapies for solid tumours. Epidermal growth factor family receptors EGFR or HER2 are commonly overexpressed in cancer and represent proven targets for CAR-T therapy; given their expression in healthy tissues it is imperative that any targeting strategy consider the potential for on-target off-tumour toxicity. MethodsHerein, we utilize high-throughput CAR screening to identify novel camelid single-domain antibody CARs (sdCARs) with high EGFR-specific CAR-T response. To optimize antigenic sensitivity of this EGFR-sdCAR, we performed progressive N-terminal truncation of the human CD8 hinge domain used as a spacer in many CAR constructs. Hinge truncation resulted in decreased CAR sensitivity to EGFR and improved selectivity for EGFR-overexpressing cells over EGFR-low target cells or healthy donor derived EGFR-positive fibroblasts. To investigate the molecular mechanism of hinge truncation, we test hinge-truncated scFv-based CARs targeting membrane proximal or membrane distal domains of EGFR-family proteins, HER2 and EGFRvIII. Finally, we proceed to test hinge variant EGFR-sdCAR functionality through in vitro and in vivo assessments in primary T cells derived from multiple donors. ResultsFor CARs targeting membrane-proximal epitopes, hinge truncation by even a single amino acid provided fine control of the antigenic sensitivity, whereas CARs targeting membrane distal domains were not sensitive to even complete hinge domain removal. Hinge-modified EGFR-sdCARs showed consistent and predictable responses in Jurkat-CAR cells and primary human CAR-T cells in vitro and in vivo. ConclusionsOverall, these results indicate that membrane-proximal epitope targeting CARs can be modified through hinge length tuning for programmable antigenic sensitivity and improved tumour selectivity. O_FIG O_LINKSMALLFIG WIDTH=196 HEIGHT=200 SRC="FIGDIR/small/360925v2_ufig1.gif" ALT="Figure 1"> View larger version (48K): org.highwire.dtl.DTLVardef@1f0db64org.highwire.dtl.DTLVardef@1d3ac43org.highwire.dtl.DTLVardef@1d270faorg.highwire.dtl.DTLVardef@f7614f_HPS_FORMAT_FIGEXP M_FIG C_FIG O_LISingle amino acid truncations of CD8-hinge domain provide precise control of CAR antigen sensitivity C_LIO_LITruncated hinge CARs show enhanced selectivity for antigen overexpressing tumour cells and decreased activity towards healthy antigen-expressing cells C_LIO_LIEpitope location is a critical factor in determining hinge sensitivity for a CAR C_LIO_LIHinge tuning can modulate CAR-T antigenic sensivity in vitro and in vivo C_LI

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Antibody Therapeutics
16 papers in training set
Top 0.1%
17.9%
2
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.1%
12.8%
3
Frontiers in Immunology
586 papers in training set
Top 1%
5.0%
4
mAbs
28 papers in training set
Top 0.1%
5.0%
5
PLOS ONE
4510 papers in training set
Top 35%
4.0%
6
OncoImmunology
22 papers in training set
Top 0.1%
4.0%
7
eBioMedicine
130 papers in training set
Top 0.4%
2.9%
50% of probability mass above
8
JAMA Network Open
127 papers in training set
Top 1%
2.8%
9
Molecular Pharmaceutics
16 papers in training set
Top 0.2%
2.4%
10
Cancer Immunology Research
34 papers in training set
Top 0.2%
2.1%
11
Blood Advances
54 papers in training set
Top 0.6%
2.1%
12
Cancer Immunology, Immunotherapy
11 papers in training set
Top 0.1%
1.9%
13
Cell Reports Medicine
140 papers in training set
Top 3%
1.9%
14
Frontiers in Pharmacology
100 papers in training set
Top 2%
1.8%
15
Human Vaccines & Immunotherapeutics
25 papers in training set
Top 0.4%
1.8%
16
Frontiers in Oncology
95 papers in training set
Top 3%
1.3%
17
Transplantation
13 papers in training set
Top 0.3%
1.3%
18
Nature Communications
4913 papers in training set
Top 57%
1.1%
19
Vaccine
189 papers in training set
Top 2%
0.9%
20
Immunology
29 papers in training set
Top 0.8%
0.9%
21
Bioinformatics
1061 papers in training set
Top 9%
0.9%
22
Vaccines
196 papers in training set
Top 2%
0.8%
23
Clinical and Translational Science
21 papers in training set
Top 0.9%
0.8%
24
Scientific Reports
3102 papers in training set
Top 72%
0.8%
25
Cellular and Molecular Bioengineering
21 papers in training set
Top 0.3%
0.8%
26
BMJ Open
554 papers in training set
Top 13%
0.7%
27
Cytotherapy
14 papers in training set
Top 0.4%
0.7%
28
International Journal of Radiation Oncology*Biology*Physics
21 papers in training set
Top 0.5%
0.7%
29
Clinical Cancer Research
58 papers in training set
Top 2%
0.5%
30
iScience
1063 papers in training set
Top 40%
0.5%